Literature DB >> 7505873

A new variant of serosubtype P1.16 in Neisseria meningitidis from Norway, associated with increased resistance to bactericidal antibodies induced by a serogroup B outer membrane protein vaccine.

E Rosenqvist1, E A Høiby, E Wedege, D A Caugant, L O Frøholm, B T McGuinness, J Brooks, P R Lambden, J E Heckels.   

Abstract

Based on differences in reaction pattern with monoclonal antibodies against the P1.16 epitope, a new variant of the class 1 protein in Neisseria meningitidis serogroup B was identified in Norway. A single amino acid deletion was revealed when the part of the gene region encoding the second variable region of the protein was sequenced. This new variant was designated P1.16c. About 5% of the B:15:P1.7,16 strains in Norway from the time period 1987-1991 were P1.16c. In a localized area in Southern Norway, 5/8 (62%) of the P1.7,16 strains were P1.16c. The P1.16b mutant, recently described in England, was not found among the Norwegian meningococcal isolates. Strains carrying the P1.16c mutation showed increased resistance to bactericidal killing, not only by P1.16-specific monoclonal antibodies, but also by the sera from individuals immunized with a vaccine based on outer membranes from a B:15:P1.7,16 strain.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7505873     DOI: 10.1006/mpat.1993.1070

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  16 in total

1.  Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine.

Authors:  E R van der Voort; P van der Ley; J van der Biezen; S George; O Tunnela; H van Dijken; B Kuipers; J Poolman
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial.

Authors:  E Wedege; E A Høiby; E Rosenqvist; G Bjune
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

3.  Fine mapping of outer membrane protein P2 antigenic sites which vary during persistent infection by Haemophilus influenzae.

Authors:  B Duim; L Vogel; W Puijk; H M Jansen; R H Meloen; J Dankert; L van Alphen
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

4.  Meningococcal disease: shifting epidemiology and genetic mechanisms that may contribute to serogroup C virulence.

Authors:  Jessica R Macneil; Jennifer D Thomas; Amanda C Cohn
Journal:  Curr Infect Dis Rep       Date:  2011-08       Impact factor: 3.725

5.  Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team.

Authors:  M L Tondella; T Popovic; N E Rosenstein; D B Lake; G M Carlone; L W Mayer; B A Perkins
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

6.  The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB.

Authors:  D R Martin; N Ruijne; L McCallum; J O'Hallahan; P Oster
Journal:  Clin Vaccine Immunol       Date:  2006-04

7.  Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine.

Authors:  E Rosenqvist; E A Høiby; E Wedege; K Bryn; J Kolberg; A Klem; E Rønnild; G Bjune; H Nøkleby
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

8.  Proposed standardization of Neisseria meningitidis PorA variable-region typing nomenclature.

Authors:  C T Sacchi; A P Lemos; M E Brandt; A M Whitney; C E Melles; C A Solari; C E Frasch; L W Mayer
Journal:  Clin Diagn Lab Immunol       Date:  1998-11

9.  Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine.

Authors:  Elisabeth Wedege; Betsy Kuipers; Karin Bolstad; Harry van Dijken; L Oddvar Frøholm; Clementien Vermont; Dominique A Caugant; Germie van den Dobbelsteen
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

10.  The meningococcus tamed?

Authors:  A J Pollard; E R Moxon
Journal:  Arch Dis Child       Date:  2002-07       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.